Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2

Free Radical Biology and Medicine

Volumn 46, Issue 12, 2009, Pages 1677-1685

  Kowluru, Renu A ^a   Kanwar, Mamta ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antioxidants; Diabetic retinopathy; Endothelial cells; Free radicals; Matrix metalloproteinase; Oxidative stress

Indexed keywords

ANTIOXIDANT; GELATINASE A; GLUCOSE; MATRIX METALLOPROTEINASE 14; SUPEROXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; COW; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RETINA CELL; RETINOPATHY; STREPTOZOCIN DIABETES;

ANIMALS; APOPTOSIS; CATTLE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FREE RADICAL SCAVENGERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS; RATS; RETINA; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STREPTOZOCIN; SUPEROXIDES;

RATTUS;

EID: 67349209321     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.03.024     Document Type: Article

References (55)

1. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
2. Kowluru R.A., Kern T.S., and Engerman R.L. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic. Biol. Med. 22 (1991) 587-592
3. Kowluru R.A., Tang J., and Kern T.S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50 (2001) 1938-1942
4. Kowluru R.A., and Abbas S.N. Diabetes-induced mitochondrial dysfunction in the retina. Investig. Ophthalmol. Vis. Sci. 44 (2003) 5327-5334
5. Feldmen E.L. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J. Clin. Invest. 111 (2003) 431-433
6. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
7. Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., Liou G.I., and Caldwell R.W. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets 6 (2005) 511-524
8. Kanwar M., Chan P.S., Kern T.S., and Kowluru R.A. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Investig. Ophthalmol. Vis. Sci. 48 (2007) 3805-3811
9. Kowluru R.A., Kowluru V., Ho Y.S., and Xiong Y. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic. Biol. Med. Sci. 41 (2006) 1191-1196
10. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11 (2006) 1696-1701
11. Itoh Y., and Seiki M. CMT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 206 (2006) 1-8
12. Liotta L.A. Probing the depths of degradation: matrix metalloproteinase-2 and endometrial menstrual breakdown. J. Clin. Invest. 97 (1996) 273-274
13. Pfeilschifter J., Eberhardt W., and Huwiler A. Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur. J. Pharmacol. 429 (2001) 279-286
14. Cox M.J., Sood H.S., Hunt M.J., Chandler D., Henegar J.R., Aru G.M., and Tyagi S.C. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am. J. Physiol, Heart Circ. Physiol. 282 (2002) H1197-H1205
15. Ho F.M., Liu S.H., Lin W.W., and Liau C.S. Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells. J. Cell. Biochem. 101 (2007) 442-450
16. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 211-242
17. Das A., McGuire P.G., Eriqat C., Ober R., DeJuan Jr. E., Williams G.A., McLamore A., Biswas J., and Johnson D.W. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Investig. Ophthalmol. Vis. Sci. 40 (1999) 809-813
18. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., and Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21 (2001) 28-33
19. Giebel S.J., Menicucci G., McGuire P.G., and Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest. 85 (2005) 567-607
20. Shiau M.Y., Tsai S.T., Tsai K.J., Haung M.L., Hsu Y.T., and Chang Y.H. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt. Sinai J. Med. 73 (2006) 1024-1028
21. Yang R., Liu H., Williams I., and Chaqour B. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann. N.Y. Acad. Sci. 1103 (2007) 196-201
22. Navaratna D., McGuire P.G., Menicucci G., and Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56 (2007) 2380-2387
23. Mizutani M., Kern T.S., and Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 97 (1996) 2883-2890
24. Kern T.S., Tang J., Mizutani M., Kowluru R.A., Nagaraj R.H., Romeo G., Podesta F., and Lorenzi M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Investig. Ophthalmol. Vis. Sci. 41 (2000) 3972-3978
25. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., and Levison S.W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47 (2002) S253-S262
26. Kowluru R.A., and Odenbach S. Effect of long-term administration of alpha lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53 (2004) 3233-3238
27. Kowluru R.A., Kanwar M., Chan P.S., and Zhang J.P. AREDS-based micronutrients inhibit retinopathy and retinal metabolic abnormalities in diabetic rats. Arch. Ophthalmol. 126 (2008) 1266-1272
28. Kowluru R.A., Kowluru A., and Kanwar M. Small molecular weight G-protein, H-Ras, and retinal endothelial cell apoptosis in diabetes. Mol. Cell. Biochem. 296 (2007) 69-76
29. Zheng F., Cornacchia F., Schulman I., Banerjee A., Cheng Q.L., Potier M Plati A.R., Berho M., Elliot S.J., Li J., Fornoni A., Zang Y.J., Zisman A., Striker L.J., and Striker G.E. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 53 (2004) 2420-2427
30. Ikejiri M., Bernardo M.M., Bonfil R.D., Toth M., Chang M Fridman R., and Mobashery S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280 (2005) 33992-34002
31. Chen W., Jump D.B., Grant M.B., Esselman W.J., and Busik J. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 44 (2003) 5016-5022
32. Kanwar M., and Kowluru R.A. Diabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implications in the development of retinopathy. Microvasc. Res. 76 (2008) 189-193
33. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020-1030
34. Barth J.L., Yu Y., Song W., Lu K., Dashti A., Huang Y., Argraves W.S., and Lyons T.J. Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 50 (2007) 2200-2208
35. Grant M.B., Caballero S., Tarnuzzer R.W., Bass K.E., Ljubimov A.V., Spoerri P.E., and Galardy R.E. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47 (1998) 1311-1317
36. Noda K., Ishida S., Inoue M., Obata K., Oguchi Y., Okada Y., and Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 44 (2003) 2163-2170
37. Noda K., Ishida S., Shinoda H., Koto T., Akoi T., Ouguchi Y., Okada Y., and Ikeda E. Hypoxia induces the expression of membrane-type 1 matrix metalloproteinase in retinal glial cells. Investig. Ophthalmol. Vis. Sci. 46 (2005) 3817-3824
38. Kohner E.M. Diabetic retinopathy. Br. Med. Bull. 45 (1989) 148-173
39. Valentin F., Bueb J.L., Kieffer P., Tschirhart E., and Atkinson J. Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells. Fundam. Clin. Pharmacol. 19 (2005) 661-667
40. Yoon S.O., Park S.J., Yoon S.Y., Yun C.H., and Chung A.S. Sustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. J. Biol. Chem. 277 (2002) 30271-30282
41. Kim K.H., Cho Y.S., Park J.M., Yoon S.O., Kim K.W., and Chung A.S. Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett. 581 (2007) 3303-3310
42. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem. Res. 33 (2008) 194-203
43. Al-Shabrawey M., Bartoli M., El-Remessy A.B., Ma G., Matragoon S., Lemtalsi T., et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 49 (2008) 3231-3238
44. Xie L., Zhu X., Hu Y., Li T., Gao Y., Shi Y., et al. Mitochondrial DNA oxidative damage triggering mitochondrial dysfunction and apoptosis in high glucose-induced HRECs. Invest. Ophthalmol. Visual Sci. 49 (2008) 4203-4209
45. Busik J.V., Mohr S., and Grant M.B. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 57 (2008) 1952-1965
46. Fu X., Parks W.C., and Heinecke J.W. Activation and silencing of matrix metalloproteinases. Semin. Cell Dev. Biol. 19 (2008) 2-13
47. Worley J.R., Thompkins P.B., Lee M.H., Hutton M., Soloway P., Edwards D.R., Murphy G., and Knäuper V. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem. J. 372 (2003) 799-809
48. Osenkowski P., Toth M., and Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J. Cell. Physiol. 200 (2004) 2-10
49. Thrailkill K.M., Bunn R.C., Moreau CS Cockrell G.E., Simpson P.M., Coleman H.N., Frindik J.P., Kemp S.F., and Fowlkes J.L. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 30 (2007) 2321-2326
50. Li Q., Sun S.J., Wang Y., Tian Y.J., and Liu M.H. The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol. 62 (2007) 485-491
51. Chung A.W., Hsiang Y.N., Matzke L.A., McManus B.M., van Breemen C., and Okon E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ. Res. 99 (2006) 140-148
52. Liu H., Yang R., Tinner B., Choudhry A., Schutze N., and Chaqour B. Cysteine-rich protein 61 and connective tissue growth factor induce de-adhesion and anoikis of retinal pericytes. Endocrinology 149 (2008) 1666-1677
53. Kwan J.A., Schulze C.J., Wang W., Leon H., Sariahmetoglu M., Sung M., et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 18 (2004) 690-692
54. Dawson V.L., and Dawson T.M. Deadly conversations: nuclear-mitochondrial cross-talk. J. Bioenerg. Biomembr. 36 (2004) 287-294
55. PZheng L., Szabo C., and Kern T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53 (2004) 2960-2967